Local implementation remains critical to patient access, even as NHS structures and responsibilities evolve. NHS decision-makers share candid perspectives on where industry engagement falls short, what adds value and what they want pharma to do differently.

Ross Margulies of Manatt Health examines MFN, CMS rulemaking and the global impact of US drug pricing reform on launch sequencing, pricing and market access strategy. 

Matt Harman of Employers Health discusses specialty risk, GLP-1 affordability, PBM reform and sustainable employer-sponsored pharmacy benefits amid US pricing change.

Drake Reiter of Priority Health discusses MFN, IRA, rebate erosion, MFP commercial spillover and how US pricing reform could reshape value and global launch strategy.

Omar Ali speaks with Jill Hanson of Centene on US pricing reform, value-based contracting, Part B drugs and site-of-care optimisation, with lessons for global access.

IPAY28 preparation, CMS drug price negotiations, negotiation deadlock, and underprepared teams. A special Fireside Chat for manufacturers preparing for future IRA negotiations.

A deep dive into MFN pricing in pharma. Learn how price spillover, launch delays, and payer pressure are changing global access strategy.

Verpora and Manatt Health — joined by a US payer voice for the first time — share insights to help manufacturers prepare for IPAY 2028, including early strategy, Part B inclusion, and evolving CMS negotiation dynamics.

In this focused 60-minute session, Verpora INSPIRE! leaders explore how international teams are adapting to rising pricing pressure, leaner resources, and increased payer scrutiny.

Can innovative contracts keep pace with curative therapies? Hemgenix’s 10-year deal in Europe might be the future. This episode unpacks how and why it worked.

Value alignment is especially difficult in rare diseases. In this Fireside Chat, we explore why and how manufacturers can create space for productive negotiation.

Payers and manufacturers often see evidence differently. This episode explores why value mismatches happen and how pharma can bridge the gap.

Can pricing adjust to differences in treatment response? Denmark shows how tiered pricing made SMA access more equitable. Learn how payers evaluate subpopulation efficacy.

Which drug goes first in a combination launch can make or break your pricing strategy. In this episode, we explore the ripple effects of sequencing decisions.

How should we price oncology therapies that deliver only incremental benefit in combinations? This Fireside Chat unpacks how payers evaluate value in complex cancer regimens.

Through the eyes of Omar Ali - a former NICE insider; a 30,000-foot full-throttle take on the collapse of NHS England's structure – and the ripple effects across commissioning, VPAG, NICE, ICBs and pharma's next move.

Performance-based agreements in China seemed impossible — until one deal showed what was possible. Watch how it built trust, access, and a path forward for markets worldwide.

Unlike cheap oral drugs, early PCSK9s were high-cost injections — and a tough sell. But one manufacturer used a VBA to secure trust and gain early access.

Watch the latest Verpora webinar on IRA Medicare drug price negotiations. Explore how CMS’s approach is shifting from IPAY 2026 to 2027, and what manufacturers should prepare for in IPAY 2028 and beyond. Access available by request.

Why do innovative contracts fail? Omar Ali and Adam Buckler explore real-world VBAs that didn’t launch—and what those failures teach us about doing it right.